Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis

Clinical Infectious Diseases

Volumn 22, Issue 5, 1996, Pages 827-833

  Kennedy, N ^a   Berger, L ^d   Curram, J ^d   Fox, R ^b   Gutmann, J ^d   Kisyombe, G M ^d   Ngowi, F I ^d   Ramsay, A R C ^d   Saruni, A O S ^d   Sam, N ^d   Tillotson, G ^d   Uiso, L O ^d   Yates, M ^d   Gillespie, S H ^c  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b MIDDLEMORE HOSPITAL   (New Zealand)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFECTION; RELAPSE; SCHOOL CHILD; TANZANIA;

EID: 9344271132     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.5.827     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. Tuberculosis morbidity - United States, 1992. MMWR Morb Mortal Wkly Rep 1993;42:696-704.
2. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: epidemiology and strategies for prevention. Tuber Lung Dis 1992;73:311-21.
3. Recommendations of the Advisory Council for the Elimination of Tuberculosis. Prevention and control of tuberculosis in U.S. communities with at-risk minority populations. MMWR Morb Mortal Wkly Rep 1992;41(RR-5):1-11.
4. Bhatti N, Law MR, Morris JK, Halliday R, Moore-Gillon J. Increasing incidence of tuberculosis in England and Wales: a study of the likely causes. BMJ 1995;310:967-9.
5. Jarallah JS, Elias AK, al Hajjaj MS, Bukhari MS, al Shareef AH, al-Shammari SA. High rate of rifampicin resistance of Mycobacterium tuberculosis in the Taif region of Saudi Arabia. Tuber Lung Dis 1993;73:113-5.
6. Grandes G, Lopez-de-Munain J, Diaz T, Rullan JV. Drug-resistant tuberculosis in Puerto Rico, 1987-1990. Am Rev Respir Dis 1993;148:6-9.
7. Centers for Disease Control. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons - Florida and New York, 1988-1991. MMWR Morb Mortal Wkly Rep 1991;40:585-91.
8. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:1514-21.
9. Chadwick M, Nicholson G, Gaya H. Combination chemotherapy with ciprofloxacin for infection with Mycobacterium tuberculosis in mouse models. Am J Med 1989;87(suppl 5A):35S-6S.
10. Kahana LM, Spino M. Ciprofloxacin in patients with mycobacterial infections: experience in 15 patients. DICP 1991;25:919-24.
11. Mohanty KC, Dhamgaye TM. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest 1993;104: 1194-8.
12. Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tuber Lung Dis 1992;73:59-67.
13. Kohno S, Koga H, Kaku M, Maesaki S, Hara K. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 1992;102:1815-8.
14. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993;37:407-13.
15. Klemens SP, Sharpe CA, Rogge MC, Cynamon MH. Activity of levofioxacin in a murine model of tuberculosis. Antimicrob Agents Chemother 1994;38:1476-9.
16. Gonzalez MA, Uribe F, Moisen SD, et al. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1984;26:741-4.
17. Garcia-Rodriguez JA, Gomez-Garcia AC. In-vitro activities of quinolones against mycobacteria. J Antimicrob Chemother 1993;32:797-808.
18. Wise R, Baldwin DR, Andrews JM, Honeybourne D. Comparative pharmacokinetic disposition of fluoroquinolones in the lung. J Antimicrob Chemother 1991;28(suppl C):65-71.
19. Salomon N, Perlman DC, Goldstein S. Special problems in treating tuberculosis [letter]. Ann Intern Med 1994;120:440-1.
20. Kennedy N, Fox R, Kisyombe GM, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis 1993;148:1547-51.
21. Collins CH, Grange JM, Yates MD. Organization and practice in tuberculosis bacteriology. London: Butterworths, 1985;87-97.
22. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993;329:784-91.
23. Mitchison DA. Understanding the chemotherapy of tuberculosis - current problems. J Antimicrob Chemother 1992;29:477-93.
24. Anonymous. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1974;2:1100-6.
25. British Thoracic and Tuberculosis Association. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial. Lancet 1976;2:1102-4.
26. Bass JB Jr, Farer LS, Hopewell PC, et al. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994;149:1359-74.
27. Kennedy N, Fox R, Uiso L, Ngowi FI, Gillespie SH. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis. J Antimicrob Chemother 1993;32:897-902.
28. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991;324:289-94.
29. Schurmann D, Bergmann F, Jautzke G, Fehrenbach J, Mauch H, Ruf B. Acute and long-term efficacy of antituberculous treatment in HIV-seropositive patients with tuberculosis: a study of 36 cases. J Infect 1993;26:45-54.
30. Perriens JH, Colebunders RL, Karahunga C, et al. Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire. Am Rev Respir Dis 1991;144:750-5.
31. Hawken M, Nunn P, Gathua S, et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 1993;342:332-7.
32. Murray CJL, DeJonghe E, Chum HJ, Nyangulu DS, Salomao A, Styblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991;338:1305-8.
33. Kamolratanakul P, Chunhaswasdikul B, Jittinandana A, Tangcharoensathien V, Udomrati N, Akksilp S. Cost-effectiveness analysis of three short-course anti-tuberculosis programmes compared with a standard regimen in Thailand. J Clin Epidemiol 1993;46:631-6.